Halozyme Therapeutics Incorporated News - HALO

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS PR Newswire SAN DIEGO, Oct. 31, 2024 Total...

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE PR Newswire SAN DIEGO, Oct. 24...

Halozyme to Report Third Quarter 2024 Financial and Operating Results

Halozyme to Report Third Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO, Oct. 23, 2024 SAN...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use

ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use Commercial Drone market expected to grow at 23.7 CAGR (Compound...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE® PR...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

biotechinvestor1 6 hours ago

New Enhanze phase 3 study in a new large TAM indication posted today:

"A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren's Disease"

https://clinicaltrials.gov/study/NCT06684847?intr=Ph20&sort=StudyFirstPostDate&rank=1

👍️ 1

Fred Kadiddlehopper 7 hours ago

Do you think it unusual that they are going ahead with a subcu trial before establishing the viability of their infusible version of sabirnitug?

👍️0

biotechinvestor1 1 day ago

What are you seeing in terms of new patents?

👍️0

biotechinvestor1 2 days ago

You wouldn't know this by looking at its beautiful chart, but Halozyme is still trading at bargain valuations not only compared to industry, S&P but also to its own 5-year averages:

Trailing PE's:
Halozyme today: 19.8
Halozyme 5-Year Average: 30.0
S&P 500 Index Average: 30.9
Pharmaceuticals Industry Average: 47.9

Forward PE's:
Halozyme today: 12.7
Halozyme 5-Year Average: 22.9
S&P 500 Index Average: 23.3
Pharmaceuticals Industry Average: 17.7

Forward PEG's:
Halozyme today: 0.5
Halozyme 5-Year Average: 0.8
S&P 500 Index Average: 2.0
Pharmaceuticals Industry Average: 1.0

Source: LSGE Stock Report Plus

👍️ 1

stockrafter 2 days ago

Couple of recently found bread crumbs....

....posting before they get moldy, while we wait for the Geron patent clarification......

Translating directly from Koren to English has to be tough, but these two translation are readable and give some insight into the competition, and Halozyme. Showing they not afraid of talking about their competition.

https://www.mk.co.kr/en/it/11164437
https://www.mk.co.kr/en/it/11164459

Cute...give the guy a view, n a thumbs up for simplicity....https://www.youtube.com/shorts/oa1wv7QrduU

Using Firefox set to plain text......one can read the blurred out tables...not a lot of details, but a good brief summary, IMO......https://dcf.fm/products/halo-business-model-canvas

Interesting TM was filed only a week or so before usage..... https://dcf.fm/products/halo-business-model-canvas

A few more interesting patents to make one wonder popped up......

SR

👍 1

maumar 4 days ago

https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-darzalex-faspro-darzalex-as-subcutaneous-monotherapy-for-high-risk-smoldering-multiple-myeloma

"If approved, DARZALEX FASPRO® will become the first treatment option for patients with smoldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before the onset of active disease and the occurrence of end organ damage
....
Smoldering multiple myeloma is an early precursor of active multiple myeloma, where abnormal cells can be detected in the bone marrow, but patients are typically asymptomatic.2 Fifteen percent of all cases of newly diagnosed multiple myeloma are classified as smoldering multiple myeloma, and half of those diagnosed with high-risk disease will progress to active multiple myeloma within two years."

If approved, this is potentially a pretty big deal, especially if the US patent extension is granted.

..

👍️ 3

biotechinvestor1 4 days ago

FWD PE ratio of 20 with the EPS of $4 to $4.20 (halo's guidance for 2024) would take share price to $80-$84. We will get there in short order.

👍️ 2

biotechinvestor1 4 days ago

..."Their patent protection also provides a decent margin of safety. I think a higher FWD PE ratio around 20 would be warranted."

👍️0

biotechinvestor1 4 days ago

..."Smart management. The stock is going to exit soon from its 4-year channel. This is fishing in a barrel for an investor."

👍️ 1

biotechinvestor1 4 days ago

... "Sorry, my last message was truncated:

..."It also decreases the cost of the API for its licensed BP users to avoid future competition on pricing.

👍️ 1

biotechinvestor1 4 days ago

Sorry, my last message was truncated:

..."The company puts a second tier licensing in place (MDASE) to grab a royalty on competing providers, as ENHANZE is sold on an exclusive license per class of drug.

👍️0

biotechinvestor1 4 days ago

Couple of smart posts from another board:

"Bashing on this name from uninformed analysts will disappear. The patents are extended for 5 years.

👍️ 1

biotechinvestor1 4 days ago

Nice post. Where is EasyComeandGo? He was one of the permabears who used to bash Halo's returns. He was wrong then and is now.

👍️ 2

MysticalGladiator72 4 days ago

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
https://finance.yahoo.com/news/heres-much-1000-investment-halozyme-133006599.html

Its even higher after today.

👍 1

biotechinvestor1 4 days ago

You are incorrect. EU patent recieved an extension to 2029. Assuming US gives the same extension Halozyme received in EU, US patent will also extend to March 2029 (per halozyme)

Halozyme has sumbitted this extension request. They are optimistic it will be granted just as it was in EU and they expect a decision soon.

Also, you are talking about patents specific to rhuph20 with the specific structure used in Enhanze. As Chief Legal Officer mentioned in the last CC, halozyme performed thousands of experiments on various modification to the enzyme and applied for patents to all these modifications. Many of these modification patents were filed later than the one for Enhanze and will expire later. This is the whole reason behind MDASE licensing.

👍️ 2

Fred Kadiddlehopper 4 days ago

I'm assuming Alteogen and partners will not bring its rhuPH20 combo products to market until after the Halozyme patent expires, which is in about 2.5 years if memory serves.

👍️0

biotechinvestor1 4 days ago

That's good news for Halozyme. More licensing fee that Alteogen will have to pay halozyme either under MDASE or through patent infringement fees.

Don't forget halozyme hired the Chief Legal Officer of Qualcome a few years back and he has been preparing for a powerful startegy since.

👍️ 2

maumar 4 days ago

Alteogen signs a partnership for SC Enhertu. Stock hits new all time high, up 567% from a year ago, over 3,000% in five years. Economics of the deal seem attractive.

👍️ 1

maumar 5 days ago

Actually, I own quite a few shares, for better or worse. It's a high risk, hopefully high reward stock. Their market cap is still lower than their cash. I hope Halo gets lucky with this one too, though the market still thinks their drug is a long shot. Obviously, a partnership with big pharma could quickly change that and would benefit both Abos and Halo.

👍️ 1

Fred Kadiddlehopper 5 days ago

ABOS has had a nice run up. Are you still looking at it?

👍️0

maumar 5 days ago

What?!!! If you mean me be by "permabear", I have never made those predictions. That's ridiculous.

👍️0

Howeeme 5 days ago

Yes. If it makes sense.

👍️0

Fred Kadiddlehopper 5 days ago

You're talking about dilution, not cash on hand, aren't you, Howee?

👍️0

Howeeme 5 days ago

Halo has plenty of cash and stock to spend a couple billion right now if it made sense.

👍️0

Fred Kadiddlehopper 5 days ago

HALO doesn't have the cash to buy anything right now.

👍️0

Howeeme 5 days ago

Doesn’t really make sense to get into manufacturing which is low margin vs high margin licensing. Use excess cash to find other high margin license products. I would say that the cdmo deal is happening in good part because Halo gave their blessing and is staying as a large customer.

👍️ 2

Roger1 5 days ago

Wonder if HALO wants Cdmo. At the low buyout offer, they could sweeten the offer and lock up production facilities forever. It would be a win win for shareholders of both companies.

👍️ 1

biotechinvestor1 6 days ago

There is lot of chatter about M&A and animal spirits in the biopharma sector with the upcoming lax antitrust administration. Don't be surprised if big pharma is salavating over Halo's superb EPS growth.

👍️ 1

biotechinvestor1 6 days ago

https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios

Currently at a 2024 PE of 15 (see link above). With the superb execution we are seeing from Halo, we will be at minimum PE of 20 by year end (barring market foolishness). That will put us around $80. If not, keep buying hand-over-fist because Mr. Market can defy fundamentals only for so long. It's ultimately all about earnings and profit margins and this is why halo has been and will continue to be a winner.

👍️ 1

Fred Kadiddlehopper 6 days ago

Avid Bioservices (CDMO) to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction

How this affects HALO, if at all, remains to be seen.
https://ih.advfn.com/stock-market/NASDAQ/avid-bioservices-CDMO/stock-news/94855278/avid-bioservices-to-be-acquired-by-gho-capital-par

👍️0

biotecholdguy 6 days ago

Posters...
Be nice! We're entering into an amazing new era, filled with optimism for every business in this country.
No room for poking fun at pessimism. They'll come around & also rejoice.

👍️0

biotechinvestor1 6 days ago

Agreed. It is hilarious. That sticky is from permabear who (along with the board moderator) has consistently predicted doom and gloom for a company with amazing EPS growth and at low PE. Their predictions in $teens, $20's, twice in $30's, $40 and twice in $50's were proven unhelpful.

👍️ 1

MysticalGladiator72 6 days ago

So true.
Look at the sticky thats still up.
Hilarious.

👍 1

biotechinvestor1 6 days ago

Fun to look back at predictions and see how they panned out. See the chain of posts below.

👍️ 1

halofan 1 week ago

They can’t be so stupid. They must have another agenda.

👍 1

Howeeme 1 week ago

Goes back to my previous post of which analysts actually care and which don’t. Tell me how an analyst can even put out a report like that. It’s embarrassing.

👍️ 2

Fred Kadiddlehopper 1 week ago

LOL! He'd have competition there. I think Eun Yang still has her PT at $5.00.

👍️0

Howeeme 1 week ago

Joe needs to sharpen his pencil. Maybe he should move to Jeffries.

👍️ 2

Fred Kadiddlehopper 1 week ago

Piper Sandler's Joe Catanzaro maintains neutral and raises PT from $51-$52

👍️0

biotechinvestor1 1 week ago

Halozyme is about to go through another major re-rating by the market; similar to what happened 2019-2020 when it went from $15 to $50.

Folks are waking up to its amazing EPS growth and fat profit margin.

Put a 20 multiple on the 2024 EPS of >$4 and you see we are headed to > $80 in short order

👍️ 1

biotechinvestor1 1 week ago

I agree with your observation: "It's more clear now how well the company is doing and how much power the earnings have moving forward. I'm officially removing my drifting predication and see some real upside in the future."

Barring market volatility, expect a sustained multi-week run up in value toward a 20-30 PE ratio (2024). Currently we are at around PE of 13-14.

2024 remaining catalysts:

1) OPDIVO SC FDA approval in December
2) US ENHANZE manufacturing patent extension and the earnings guaidance update that will go along with it (juat like we saw with EU patent extension earlier this year)
3) Surprise new deal(s).

👍️ 2

biotechinvestor1 2 weeks ago

It’s headed to $70’s

👍️ 1

biotecholdguy 2 weeks ago

YES SHE IS !!

👍️0

Howeeme 2 weeks ago

Nice action today. First time I’ve seen Halo consistently holding gains all day long. Sensed some aggravation with some analysts with the positive earnings surprise. Not surprised to see the upgrades from the analysts who really know the company and silence from the big institutional analysts who got egg on their face. It’s more clear now how well the company is doing and how much power the earnings have moving forward. I’m officially removing my drifting predication and see some real upside in the future. Helen is doing a great job.

👍 3

Fred Kadiddlehopper 2 weeks ago

HC Wainwright Mitch Kapoor maintains buy and raises PT from $65-$68

👍️0

Fred Kadiddlehopper 2 weeks ago

JMP Securities Jason Butler maintains outperform and raises PT from $72-$73

👍️0

OncoJock 2 weeks ago

Sorry I got Alteogen mixed up with Harpoon. I'm writing about a lot of different drugs and drug companies these days.

March 11, 2024
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon’s common stock will no longer be publicly traded or listed on the Nasdaq Stock Market.

“We continue to augment and diversify our oncology pipeline with innovative approaches to help people with cancer worldwide,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “We are pleased to welcome our Harpoon colleagues to Merck and look forward to working together to advance a novel portfolio of T-cell engagers, including MK-6070.”

👍️0

biotechinvestor1 2 weeks ago

Halozyme price target raised by $3 at H.C. Wainwright

https://m.thefly.com/new-landing/4011153?utm_source=https%3A%2F%2Fwww.etrade.wallst.com%2F&utm_medium=referral&utm_campaign=referral_traffic

👍️ 2

biotechinvestor1 2 weeks ago

My pleasure! Halozyme blew knocked it iut if the park. Revenue $290m vs $251 expected; adj eps $1.27 vs $.98 expected. Upped annual forecast.

$HALO Don’t be surprised to see analyst upgrades and price target raises.
Back to $60-$70 range soon

👍️ 3

biotechinvestor1 2 weeks ago

1- Merck does not own Alteogen

2- MDASE is a win-win for all parties (Halozyme, Alteogen and Merck)

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Halozyme Therapeutics Incorporated (HALO)

Empower your portfolio: Real-time discussions and actionable trading ideas.

HALO News

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

Halozyme to Report Third Quarter 2024 Financial and Operating Results

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

HALO Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Halozyme Therapeutics Incorporated (HALO) News

Halozyme Therapeutics Incorporated (HALO)

Empower your portfolio: Real-time discussions and actionable trading ideas.

HALO News

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

Halozyme to Report Third Quarter 2024 Financial and Operating Results

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

HALO Discussion

Your Recent History

Company

Business

Popular

Get The App